close
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Altimmune, Inc. - Common Stock (NQ:ALT)

3.920 -0.080 (-2.00%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Altimmune, Inc. - Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Why Is Altimmune (ALT) Stock Up 43% Today?
Altimmune stock is rising higher on Friday with heavy trading of ALT shares after posting positive results form a clinical trial. 
Via InvestorPlace
Altimmune Inc. (NASDAQ: ALT) is One of Friday Morning’s Most Active Stocks
Via Investor Brand Network
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Software earnings were strong, while the Fed is shifting toward rate cuts. 
Via Investor's Business Daily
Topics Economy Stocks
Tale Of Two Investigational Obesity Drugs: Altimmune Stock Jumps, While Pfizer Trades Lower
Altimmune Inc (NASDAQ: ALT) announced topline results from its 48-week MOMENTUM Phase 2 obesity trial of pemvidutide  
Via Benzinga
Altimmune's Earnings Outlook
 
Via Benzinga
Preview: Altimmune's Earnings
 
Via Benzinga
Altimmune: Q1 Earnings Insights
 
Via Benzinga
Earnings Preview: Altimmune
 
Via Benzinga
Short Volatility Alert: Altimmune Inc
On Thursday, shares of Altimmune Inc (NASDAQ: ALT) experienced volatile short activity. After the activity, the stock price went down -4.02% to $5.73. The overall sentiment for ALT has been Bearish. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
It's the final day of trading this week and we're starting it with a breakdown of the biggest pre-market stock movers on Friday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 56 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  Wednesday saw 59 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  On Friday, 54 companies hit new 52-week lows. 
Via Benzinga
7 Analysts Have This to Say About Altimmune
 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday morning, 70 companies achieved new lows for the year. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's trading, 46 companies set new 52-week lows. 
Via Benzinga
5 Biotech Stocks That Could Soar Thanks To These Disruptive Healthcare Technologies
 
Via Benzinga
Metabolic Syndrome: The Silent Epidemic On The Rise And How BioRestorative Therapies Inc. Is Helping Fight It
Once a lesser-known health condition, now a problem crippling millions of people around the world: metabolic syndrome is unfortunately on the rise. 
Via Benzinga
The 3 Most Promising Biotech Innovations in 2023 and the Stocks to Buy
Here are three biotech stocks with promising innovations that could provide catalysts for their respective stocks in 2023 
Via InvestorPlace
7 Biotech Stocks With Huge Return Potential for Long-Term Investors
Although a wildly speculative sector, the low-cost, high-potential biotech stocks to buy and hold may deliver the goods for gamblers. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
7 Cheap Stocks That Are Worth Your Attention
Finding cheap stocks that are worth an investment can be tricky, but the Portfolio Grader is a tool you can use to narrow the field. 
Via InvestorPlace
BioRestorative Therapies (NASDAQ: BRTX) Is Targeting The Global Obesity Epidemic With Its Recent IP Portfolio Expansion
BioRestorative Therapies Inc (NASDAQ: BRTX) is expanding its ThermoStem® intellectual property portfolio for treatments targeting obesity, diabetes and other indications related to metabolic syndrome... 
Via Benzinga
Should You Buy Viking Therapeutics Stock After It Skyrocketed Over 60%?
Viking could have a strong rival to Novo Nordisk's Wegovy and Ozempic and Lilly's Mounjaro in the making. 
Via The Motley Fool
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP 
Via MarketBeat
Is Viking Therapeutics a Smart Buy on the Dip?
The stock recently fell around 25% for reasons that had nothing to do with its lead program. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For March 22, 2023
 
Via Benzinga
Wall Street Absolutely Loved This Biotech Stock. But It Just Crashed More Than 50%.
It's not the end of the story for this once high-flying biotech stock. 
Via The Motley Fool
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Starting at $3.75/week.

Subscribe Today